In this piece, we will take a look at the top five stocks to buy today according to billionaire Thomas Steyer. For more stocks, take a look at 10 Best Stocks to Buy Now According to Billionaire Thomas Steyer.
5. Aramark (NYSE:ARMK)
Farallon Capital’s Stake Value: $490 million
Percentage of Farallon Capital’s 13F Portfolio: 3.01%
Number of Hedge Fund Holders: 27
Aramark (NYSE:ARMK) is an American company that offers food and uniform services to a wide variety of industries such as education, security, sports, and prisons. The firm is headquartered in Philadelphia, Pennsylvania.
Farallon Capital held a $490 million stake in Aramark (NYSE:ARMK) as part of its second quarter of 2022 investments. This came through the firm owning 16 million shares of the company and it represented 3% of its investment portfolio. For the same time period, 27 out of the 895 hedge funds polled by Insider Monkey had bought the company’s shares.
Aramark (NYSE:ARMK) reported a 38% revenue growth during its latest fiscal quarter, which beat analyst expectations. At the same time, it also upgraded its annual revenue growth estimate to sit at a high end of 32%, above the 27% forecast it had previously guided. The revenue growth now places the net sales at above pre COVID levels.
Aramark (NYSE:ARMK)’s largest investor after Farallon Capital is George Soros’s Soros Fund Management which owns 3.6 million shares that are worth $110 million.
4. Boston Scientific Corporation (NYSE:BSX)
Farallon Capital’s Stake Value: $560 million
Percentage of Farallon Capital’s 13F Portfolio: 3.45%
Number of Hedge Fund Holders: 56
Boston Scientific Corporation (NYSE:BSX) is a medical device manufacturer and seller that serves the needs of surgeons and neurological and cardiovascular patients. The company is headquartered in Marlborough, Massachusetts, the United States.
Boston Scientific Corporation (NYSE:BSX) has managed to consistently beat analyst EPS estimates for its previous four quarters, as hospitals and physicians shifted their attention from coronavirus patients to those with other diseases. Bank of America paints a bright future for the company’s earnings per share, as it expects it to grow the metric by 7.4%, 11.4%, and 12.3% from 2022 end to 2024 end.
Mr. Steyer’s former hedge fund owned 15 million Boston Scientific Corporation (NYSE:BSX) shares as part of its Q2 2022 holdings, allowing it to hold a $560 million stake in the company. Insider Monkey’s 895 hedge fund survey for this year’s June quarter revealed that 56 had bought Boston Scientific Corporation (NYSE:BSX)’s shares.
Out of these, Andreas Halvorsen’s Viking Global is Boston Scientific Corporation (NYSE:BSX)’s second largest investor as it owns a $546 million stake that comes through 14.6 million shares.
3. TransUnion (NYSE:TRU)
Farallon Capital’s Stake Value: $596 million
Percentage of Farallon Capital’s 13F Portfolio: 3.67%
Number of Hedge Fund Holders: 24
TransUnion (NYSE:TRU) is a risk and information solutions provider that offers a variety of products and services such as consumer reports, insights reports, and business analytics. The company is headquartered in Chicago, Illinois, the United States.
By the end of this year’s June quarter, Farallon Capital had owned 7.4 million TransUnion (NYSE:TRU) shares which were worth $596 million and represented 3.67% of its investment portfolio. During the same time period, 24 of the 895 hedge funds polled by Insider Monkey had also invested in the company.
TransUnion (NYSE:TRU) is one of the world’s largest credit reporting agencies, and it has data of more than 200 million Americans and over 1 billion people all over the globe. Its primary market, the big data segment, is estimated to be worth a whopping $103 billion by 2027, leaving the company with a large playing field – a fact that is compounded when we see that it is one of only three of the world’s largest credit rating agencies.
TransUnion (NYSE:TRU)’s largest investor after Farallon Capital is Tim Hurd and Ed Magnus’s BlueSpruce Investments which owns 5 million shares that are worth $400 million.
2. Thermo Fisher Scientific Inc. (NYSE:TMO)
Farallon Capital’s Stake Value: $675 million
Percentage of Farallon Capital’s 13F Portfolio: 4.15%
Number of Hedge Fund Holders: 93
Thermo Fisher Scientific Inc. (NYSE:TMO) is a life sciences services and analytical instruments provider that is based out of Waltham, Massachusetts, the United States. The firm provides products such as reagent kits, verification fluids, preparation and transportation systems, and cultured media to biotechnology and pharmaceutical companies.
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the strongest dividend stocks in its industry and on the stock market. The company pays 30 cent dividend for a 0.23% yield. Over the past two decades, the firm has paid out 16.6% in dividends and its ten year average dividend growth rate sits at 16%.
Farallon Capital held a $675 million stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter of this year, which came in the form of 1.2 million shares and represented 4.15% of its investment portfolio. Insider Monkey’s Q2 2022 895 hedge fund survey saw 93 as having invested in the company.
Thermo Fisher Scientific Inc. (NYSE:TMO)’s largest investor in our database is Ken Fisher’s Fisher Asset Management which owns 2.3 million shares that are worth $1.2 billion.
Stewart Asset Management mentioned the company in its Q2 2022 investor letter. Here is what the fund said:
“Recently we initiated two new investments. One in Thermo Fischer Scientific (NYSE:TMO), a supplier to the life sciences industry. We have followed the company for many years and the recent downturn in share price gave us a good entry price at which to invest. Thermo has had strong earnings growth for many years and is led by a superb team. The company’s recent acquisitions make it a full-service supplier to the biopharma and biotech industries.”
1. IQVIA Holdings Inc. (NYSE:IQV)
Farallon Capital’s Stake Value: $697 million
Percentage of Farallon Capital’s 13F Portfolio: 4.29%
Number of Hedge Fund Holders: 53
IQVIA Holdings Inc. (NYSE:IQV) is a data analytics and research solutions provider to the healthcare industry. The firm serves clients in North and South America, Europe, Africa, and the Asia Pacific region. It is headquartered in Durham, North Carolina, the United States.
Farallon Capital owned 3.2 million IQVIA Holdings Inc. (NYSE:IQV) shares as part of its Q2 2022 holdings. These allowed it to own a $697 million stake in the company. For the same time period, an Insider Monkey survey of 895 hedge funds showed that 53 had also bought IQVIA Holdings Inc. (NYSE:IQV)’s shares.
IQVIA Holdings Inc. (NYSE:IQV) posted a 7% annual revenue growth for its second fiscal quarter, which saw the company rake in $3.5 billion in revenue. This let the firm post $1.5 billion in free cash flow on a trailing twelve month basis, for a strong FCF return on equity of 29%.
IQVIA Holdings Inc. (NYSE:IQV)’s largest investor in our database after Farallon Capital is William Von Mueffling’s Cantillon Capital Management which owns 1.5 million shares that are worth $341 million.
Disclosure: None. You can also take a look at 10 Best Long-Term Stocks to Buy Now and 10 Long-Term Stocks to Buy According to Billionaire Mario Gabelli.
